New Haven Pharmaceuticals provides $0 Co-Pay Card to patients

Extended-release DURLAZA® is available to most patients with no out-of-pocket costs

  • Commercially insured patients pay $0 out-of-pocket for a 30-day supply of DURLAZA worth up to $150
  • Even if patients are uninsured or underinsured, they can save an average of 70% on a 30-day supply of DURLAZA worth up to $150†‡§
  • Prescription status helps you with patient refills

DURLAZA can assist you with patient adherence

The prescription status of DURLAZA provides you and your patients with ideal refill control to ensure they receive the medication you desire compared to OTC regimens.

Download Co-Pay Card

Programs to increase access to DURLAZA (aspirin)

DURLAZA Cares is a comprehensive array of patient support programs that help a broad range of patients gain access to DURLAZA.

Prior authorization assistance

This program is for patients with health insurance requiring prior authorization for a DURLAZA prescription. Your office staff can contact our sanctioned third-party company, who will work directly with payers to facilitate the authorization process.

Learn more about prior authorization assistance by calling 1.844.751.7751 or emailing

Additional financial assistance for select patients

DURLAZA has partnered with the nonprofit organization, Patient Services, Inc. (PSI), to support underserved patients. Patients must meet certain income criteria to be eligible. By contacting PSI, your patients in the greatest financial need may be able to get help with insurance premiums and co-pay costs through the PSI secondary payment program. PSI also advocates for your patients and can connect them to external ancillary resources.

You or your patients can contact PSI regarding financial assistance. Call 1.800.366.7741 or visit for more information.

Terms and conditions apply.

Patients who are uninsured, or insured but not covered, may be required to pay an average of $40 toward a 30-day supply of DURLAZA.

§ Offer not valid for prescriptions reimbursed under Medicaid, a Medicare drug benefit plan, or other federal or state healthcare programs (such as medical assistance programs).

Important Safety Information

Indications and Usage

DURLAZA® (aspirin) Extended-Release Capsules 162.5 mg is indicated:

  • to reduce the risk of death and myocardial infarction (MI) in patients with chronic coronary artery disease, such as patients with a history of MI or unstable angina pectoris or with chronic stable angina;
  • to reduce the risk of death and recurrent stroke in patients who have had an ischemic stroke or transient ischemic attack.

Limitation of Use: Use immediate-release aspirin, not DURLAZA in situations where a rapid onset of action is required (such as acute treatment of myocardial infarction or before percutaneous coronary intervention).

Important Safety Information

Contraindications: DURLAZA is contraindicated in patients with a hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) and in patients with the syndrome of asthma, rhinitis, and nasal polyps. DURLAZA may cause severe urticaria, angioedema, or bronchospasm.

Warnings and precautions:

  • DURLAZA increases the risk of bleeding. Risk factors for bleeding include the use of other drugs that increase the risk for bleeding.
  • DURLAZA may cause gastric ulceration and bleeding. Avoid DURLAZA in patients with active peptic ulcer disease.
  • DURLAZA can cause fetal harm when administered to a pregnant woman, including low birth weight, increased incidence for intracranial hemorrhage in premature infants, stillbirths and neonatal death. Avoid DURLAZA in the third trimester of pregnancy.

Adverse reactions: The following adverse reactions have been reported for products containing low dose aspirin:

  • Central Nervous System: Agitation, cerebral edema, coma, confusion, dizziness, headache, lethargy, seizures;
  • Fluid and Electrolyte: Hyperkalemia, metabolic acidosis, respiratory alkalosis;
  • Gastrointestinal: Dyspepsia, hepatic enzyme elevation, hepatitis, Reye's Syndrome;
  • Renal: Interstitial nephritis, papillary necrosis, proteinuria, renal insufficiency and failure.

Drug interactions:

  • Alcohol: Do not take DURLAZA 2 hours before or 1 hour after consuming alcohol.
  • Dual inhibition of the renin-angiotensin system: Increased risk of renal impairment, hypotension and hyperkalemia.
  • Anticoagulant and antiplatelets: Increased risk of bleeding.
  • Anticonvulsants: Decreased phenytoin concentration and increased serum valproic acid levels.
  • Methotrexate: Increased risk of bone marrow toxicity.
  • NSAIDs: Increased risk of bleeding. Nonselective NSAIDs may interfere with the antiplatelet effect of DURLAZA.

Use in specific populations:

  • Pregnancy: Avoid use during the third trimester.
  • Hepatic Impairment: Avoid use in patients with severe impairment.
  • Renal Impairment: Avoid use in patients with GFR <10mL/min.

Please see full Prescribing Information for DURLAZA.